Skip to main content

Shimadzu, University of Tokyo Developing Lipidomics Biomarker Technologies

NEW YORK (GenomeWeb News) – Shimadzu and the University of Tokyo today announced a collaboration to develop technologies aimed at lipidomic biomarkers.

The deal, which extends until March 31, 2014, calls for the company and the school to perform joint research in topics such as the development of a biological sample pretreatment system and developing a comprehensive method for analyzing functional, membrane, and other lipids, and then applying them to the discovery of lipid biomarkers that may be associated with various diseases, including those related to lifestyles.

Shimadzu, the University of Tokyo, and Ono Pharmaceutical jointly established a sponsored laboratory within the department of lipidomics in the Graduate School of Medicine and Faculty of Medicine at the university in April in order to enable studies into low molecular weight compounds, such as bioactive and membrane lipids, "as the next area of research following genomics and proteomics," the partners said.

The parties signed the agreement last month but didn't announce it until today. Financial details were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.